| Name
|
Acetyl-(D-Trp1,D-Phe(4-Cl)2,D-Trp3,D-Arg6,D-Ala10)-LHRH
|
| Code
|
[86044-76-0]
|
| The alias
|
Acetyl-(D-Trp1,D-Phe(4-Cl)2,D-Trp3,D-Arg6,D-Ala10)-LHRH
|
| Sequence (single letter abbreviation)
|
Ac-w-chloro-fwSYrLRPa-NH2
|
| Sequence (three-letter abbreviation)
|
Ac-D-Trp-4-chloro-D-Phe-D-Trp-Ser-Tyr-D-Arg-Leu-Arg-Pro-D-Ala-NH2?(trifluoroacetate salt)
|
| A basic description
|
As a potent LHRH agonist, histrelin stimulates LH and FSH release and inhibits the actions of sex steroids on the male and female reproductive tracts. Its potency in vivo and in vitro is similar to that of the D-Trp6-containing analog. Especially because of its high water solubility and greater lipophilic character, histrelin appears promising for clinical application.Slow-release implants containing histreline implants were approved for the palliative treatment of advanced hormone-dependent prostate cancer.
|
| solubility
|
|
| The molecular weight
|
1457.1
|
| Chemical formula
|
C55H75N17O13
|
| The purity
|
80%，90%，95%，98%，99%
|
| Weight
|
1mg,5mg,10mg,50mg,100mg,1g
|
| Storage conditions
|
Store at -20°C. Keep tightly closed. Store in a cool dry place.
|
| Annotation
|
|
| Documents
|
|
| Figures
|
|
| Reference
|
S.E.Kirk et al., Endocrinology, 135, 876 (1994)
A.C.Dalkin et al., Endocrinology, 139, 2818 (1998)
L.L.Burger et al., Endocrinology, 142, 3435 (2001)
K.A.Prendergast et al., Biol. Reprod., 70, 364 (2004)
|
| The C-terminal
|
|
| The N-terminal
|
|
| Chemical bridge
|
|